Ranjan Chrisanthar

581 total citations
9 papers, 327 citations indexed

About

Ranjan Chrisanthar is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ranjan Chrisanthar has authored 9 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ranjan Chrisanthar's work include Cancer-related Molecular Pathways (7 papers), BRCA gene mutations in cancer (2 papers) and Epigenetics and DNA Methylation (2 papers). Ranjan Chrisanthar is often cited by papers focused on Cancer-related Molecular Pathways (7 papers), BRCA gene mutations in cancer (2 papers) and Epigenetics and DNA Methylation (2 papers). Ranjan Chrisanthar collaborates with scholars based in Norway and United Kingdom. Ranjan Chrisanthar's co-authors include Stian Knappskog, Per Eystein Lønning, Erik Løkkevik, Bjørn Østenstad, Steinar Lundgren, Terje Risberg, Ingvil Mjaaland, Gun Anker, Johan R. Lillehaug and Vidar Staalesen and has published in prestigious journals such as PLoS ONE, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Ranjan Chrisanthar

8 papers receiving 320 citations

Peers

Countries citing papers authored by Ranjan Chrisanthar

Since Specialization

Citations

This map shows the geographic impact of Ranjan Chrisanthar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ranjan Chrisanthar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ranjan Chrisanthar more than expected).

Fields of papers citing papers by Ranjan Chrisanthar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ranjan Chrisanthar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ranjan Chrisanthar. The network helps show where Ranjan Chrisanthar may publish in the future.

Co-authorship network of co-authors of Ranjan Chrisanthar

This figure shows the co-authorship network connecting the top 25 collaborators of Ranjan Chrisanthar. A scholar is included among the top collaborators of Ranjan Chrisanthar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ranjan Chrisanthar. Ranjan Chrisanthar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function 2017 ·Breast Cancer Research and Treatment ·Synnøve Yndestad, (unknown), Stian Knappskog, Ranjan Chrisanthar, Peer K. Lilleng, Per Eystein Lønning, Hans Petter Eikesdal	18
2	Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo 2015 ·Molecular Oncology ·Stian Knappskog, (unknown), Ranjan Chrisanthar, Stephanie Geisler, Vidar Staalesen, Beryl Leirvaag, Synnøve Yndestad, (unknown), Bård Ove Karlsen, David C. Wedge, Lars A. Akslen, Peer K. Lilleng, Erik Løkkevik, Steinar Lundgren, Bjørn Østenstad, Terje Risberg, (unknown), Turid Aas, Per Eystein Lønning	21
3	Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer 2012 ·Breast Cancer Research ·Stian Knappskog, Ranjan Chrisanthar, Erik Løkkevik, Gun Anker, Bjørn Østenstad, Steinar Lundgren, Terje Risberg, Ingvil Mjaaland, Beryl Leirvaag, Hrvoje Miletić, Per Eystein Lønning	58
4	Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel 2011 ·PLoS ONE ·Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Østenstad, Steinar Lundgren, Terje Risberg, Ingvil Mjaaland, (unknown), Turid Aas, Ellen Schlichting, Hans E. Fjøsne, Arne Nysted, Johan R. Lillehaug, Per Eystein Lønning	81
5	CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer 2008 ·PLoS ONE ·Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Østenstad, Steinar Lundgren, (unknown), Terje Risberg, Ingvil Mjaaland, Lovise Mæhle, Lars Engebretsen, Johan R. Lillehaug, Per Eystein Lønning	75
6	Breast cancer prognostication and prediction in the postgenomic era 2007 ·Annals of Oncology ·Per Eystein Lønning, Stian Knappskog, Vidar Staalesen, Ranjan Chrisanthar, JR Lillehaug	47
7	Mutations and polymorphisms of the p21B transcript in breast cancer 2007 ·International Journal of Cancer ·Stian Knappskog, Ranjan Chrisanthar, Vidar Staalesen, Anne‐Lise Børresen‐Dale, Inger Torhild Gram, Johan R. Lillehaug, Per Eystein Lønning	15
8	Adjuvant treatment: the contribution of expression microarrays 2007 ·Breast Cancer Research ·Per Eystein Lønning, Ranjan Chrisanthar, Vidar Staalesen, Stian Knappskog, Johan R. Lillehaug	0
9	The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer 2006 ·Clinical Cancer Research ·Vidar Staalesen, Stian Knappskog, Ranjan Chrisanthar, Silje Nord, Erik Løkkevik, Gun Anker, Bjørn Østenstad, Steinar Lundgren, Terje Risberg, Ingvil Mjaaland, Inger Torhild Gram, Vessela N. Kristensen, Anne‐Lise Børresen‐Dale, Johan R. Lillehaug, Per Eystein Lønning	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact